Zhejiang Jiaoke: the amount of newly signed orders in the first quarter was 9.488 billion yuan, and the order stock was sufficient
At the 2021 annual performance presentation meeting held today, Zhao Junwei, financial director of Zhejiang Communications Technology Co., Ltd., said, "The amount of new orders signed by the company in the first quarter was 9.488 billion yuan, a year-on-year decrease, mainly due to the impact of the Hangzhou Asian Games. The number of new projects launched by the government decreased. With the extension of the Asian Games, the number of new projects will gradually increase. By the end of the first quarter, the company had nearly 200 unfinished projects, with a cumulative revenue of about 68 billion yuan and an unfinished amount of about 82 billion yuan. The order stock is relatively sufficient."
This text is a result of machine translation.
Related companies：
Briefing Updated 7 hours ago
· Healthcare
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
In-depth
Yesterday 05:00 PM
Apr 26, 2022 12:26 PM
Apr 21, 2022 07:07 PM
Apr 18, 2022 06:30 PM
Briefing Updated 6 hours ago
· Automotive
Gaode started the "cooling action" by taking a taxi and gave high-temperature subsidies to encourage drivers to turn on more air conditioners
Briefing Updated 6 hours ago
· Automotive
Germany started the "cooling action" by taking a taxi and gave high-temperature subsidies to encourage drivers to turn on more air conditioners
Healthcare
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Updated 32 mins ago
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Read next
In-depth
In-depth
In-depth
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.